-- First patient dosed in Phase II EXPLORE trial evaluating GT005 in people with geographic atrophy secondary to dry AMD with a mutation in the Complement Factor I gene -- -- A second Phase II trial ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular ...
Please provide your email address to receive an email when new articles are posted on . A majority of patients with age-related macular degeneration treated with investigational gene therapy GT005 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results